Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment

WSJDec 21 05:00

Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

BusinesswireDec 21 04:46

Vertex Announces U.S. FDA Approval for TRIKAFTA (Elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

BusinesswireDec 21 04:35

Vertex (VERX.US) non-addictive painkillers encounter the "placebo effect" which analysts say brings setbacks.

Vertex Pharmaceuticals' non-addictive medication has helped patients relieve back pain in mid-term trials, but the effectiveness is not much better than that of a placebo.

Zhitong FinanceDec 19 21:29

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

BusinesswireDec 19 19:00

Vertex Insider Sold Shares Worth $1,060,932, According to a Recent SEC Filing

MT NewswiresDec 19 05:17